166 related articles for article (PubMed ID: 27264006)
41. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.
Rupoli S; Da Lio L; Sisti S; Campanati G; Salvi A; Brianzoni MF; D'Amico S; Cinciripini A; Leoni P
Ann Hematol; 1994 Apr; 68(4):205-12. PubMed ID: 8003563
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
43. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
44. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
45. [Myelofibrosis with myeloid metaplasia. A study of 24 consecutive patients].
Bettini R; Redaelli S; Marzetta K; Maino C; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2004; 95(7-8):358-64. PubMed ID: 15303545
[TBL] [Abstract][Full Text] [Related]
46. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
[TBL] [Abstract][Full Text] [Related]
47. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival.
Varki A; Lottenberg R; Griffith R; Reinhard E
Medicine (Baltimore); 1983 Nov; 62(6):353-71. PubMed ID: 6633248
[TBL] [Abstract][Full Text] [Related]
48. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
49. C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis.
Lucijanic M; Galusic D; Krecak I; Sedinic M; Soric E; Holik H; Perisa V; Moric Peric M; Zekanovic I; Stoos-Veic T; Kusec R
Leuk Lymphoma; 2020 Dec; 61(12):2969-2974. PubMed ID: 32654566
[TBL] [Abstract][Full Text] [Related]
50. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
Caramazza D; Begna KH; Gangat N; Vaidya R; Siragusa S; Van Dyke DL; Hanson C; Pardanani A; Tefferi A
Leukemia; 2011 Jan; 25(1):82-8. PubMed ID: 20944670
[TBL] [Abstract][Full Text] [Related]
51. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
Tefferi A; Mesa RA; Nagorney DM; Schroeder G; Silverstein MN
Blood; 2000 Apr; 95(7):2226-33. PubMed ID: 10733489
[TBL] [Abstract][Full Text] [Related]
52. Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival.
Cervantes F; Barosi G; Hernández-Boluda JC; Marchetti M; Montserrat E
Eur J Haematol; 2001 May; 66(5):324-7. PubMed ID: 11422412
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of bone marrow reticulin fibres in idiopathic myelofibrosis: evaluation of clinicopathological parameters in a scoring system.
Iványi JL; Mahunka M; Papp A; Kiss A; Telek B
Haematologia (Budap); 1994; 26(2):75-86. PubMed ID: 7890265
[TBL] [Abstract][Full Text] [Related]
54. Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.
Wu Z; Chen R; Wu L; Zou L; Ding F; Wang M; Liu X
Clin Transl Oncol; 2017 Dec; 19(12):1462-1468. PubMed ID: 28589431
[TBL] [Abstract][Full Text] [Related]
55. Prognostication in primary myelofibrosis.
Cervantes F; Pereira A
Curr Hematol Malig Rep; 2012 Mar; 7(1):43-9. PubMed ID: 22072485
[TBL] [Abstract][Full Text] [Related]
56. Gaucher Disease and Myelofibrosis: A Combined Disease or a Misdiagnosis?
Mariani S; Palumbo G; Cardarelli L; Santopietro M; Foà R; Giona F
Acta Haematol; 2018; 139(4):240-242. PubMed ID: 29945135
[TBL] [Abstract][Full Text] [Related]
57. Prognosis of myeloid metaplasia with myelofibrosis.
Chelloul N; Briere J; Laval-Jeantet M; Najean Y; Vorhauer W; Jacquillat C
Biomedicine; 1976; 24(4):272-80. PubMed ID: 990377
[TBL] [Abstract][Full Text] [Related]
58. Improving survival trends in primary myelofibrosis: an international study.
Cervantes F; Dupriez B; Passamonti F; Vannucchi AM; Morra E; Reilly JT; Demory JL; Rumi E; Guglielmelli P; Roncoroni E; Tefferi A; Pereira A
J Clin Oncol; 2012 Aug; 30(24):2981-7. PubMed ID: 22826273
[TBL] [Abstract][Full Text] [Related]
59. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
[TBL] [Abstract][Full Text] [Related]
60. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
Sazawal S; Singh N; Mahapatra M; Saxena R
Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
